The Uromigos

Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer 27.04.2024 18:17 ↓

Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.

Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer 27.04.2024 25:15 ↓

Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.

Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease 26.04.2024 35:40 ↓

Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.

Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer 26.04.2024 23:56 ↓

Jason Efstathiou and Piet Ost discuss the data for and against this approach.

Episode 311: The Uromigos Paper of the Month - The POUT Trial 23.04.2024 36:02 ↓

Alison Birtle describes adjuvant chemotherapy in bladder cancer.

Episode 310: Dosing and duration of drugs from a cost perspective 17.04.2024 28:28 ↓

Daniel Goldstein describes his work on this issue.

Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer 07.04.2024 27:13 ↓

In this second part, Matt Galsky describes the OS signal data. We also look into the future.

Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy 07.04.2024 23:09 ↓

Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.

Episode 307: Bladder-Sparing Approaches Part 2 02.04.2024 35:14 ↓

Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.

Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC 28.03.2024 29:56 ↓

Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.

Episode 305: FDA and Oncology Clinical Trials 19.03.2024 29:35 ↓

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC 11.03.2024 30:43 ↓

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

Episode 303: Community GU Oncology 05.03.2024 24:16 ↓

Michael Lattanzi discusses treatment plans and research in the community.

Episode 302: Part 2- Adjuvant Therapy in solid tumors 25.02.2024 34:37 ↓

Hans Hammers discusses trial design and patient selection in the adjuvant setting.

Episode 301: Cancer research from a global perspective. 20.02.2024 31:06 ↓

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries

Episode 300: Adjuvant PD1 Therapy in Solid Tumours 11.02.2024 42:15 ↓

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

Episode 299: Androgen receptor ligand-directed degrader BMS-986365 07.02.2024 36:40 ↓

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer

Episode 298: ASCO GU 2024 Highlights 31.01.2024 27:15 ↓

Silke, Tom and Brian cover the bases.

Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath 30.01.2024 22:46 ↓

Neeraj Agarwal addresses the issues raised at the meeting.

Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan 27.01.2024 23:58 ↓

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005

Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer 27.01.2024 32:46 ↓

Pedro Barata summarises his ASCO GU discussion on this topic.

Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer 27.01.2024 33:17 ↓

Andrea Apolo describes the results of this positive trial.

Episode 293: ASCO GU 2024: BRCAaway and CONTACT2 26.01.2024 22:21 ↓

Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.

Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer 26.01.2024 26:04 ↓

Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.

Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer 25.01.2024 31:15 ↓

Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.